AML, acute lymphoblastic leukemia (ALL) and breast cancer cells with inactive mutant ClpP (D190A) or ClpP knockout are resistant to ONC201 and ONC212, indicating the functional importance of ClpP for imipridones efficacy. Here, CLPP is linked to breast carcinoma.